Trial Profile
Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Central serous chorioretinopathy
- Focus Adverse reactions
- 24 Oct 2014 New trial record